Valuation: Aldeyra Therapeutics, Inc.

Market Cap 82.04M 71.54M 67.55M 61.34M 115M 7.87B 115M 809M 312M 4B 308M 301M 12.88B P/E 2026 *
-4x
P/E 2027 * -4.89x
Enterprise Value 82.04M 71.54M 67.55M 61.34M 115M 7.87B 115M 809M 312M 4B 308M 301M 12.88B EV / Sales 2026 *
-
EV / Sales 2027 * 12.2x
Free-Float
96.4%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Aldeyra Therapeutics, Inc.

1 day-1.45%
1 week+1.49%
Current month-8.11%
1 month-13.92%
3 months-30.61%
6 months-25.68%
Current year-73.75%
1 week 1.34
Extreme 1.345
1.49
1 month 1.33
Extreme 1.33
1.6
Current year 1.07
Extreme 1.07
5.93
1 year 1.07
Extreme 1.07
5.93
3 years 1.07
Extreme 1.07
7.2
5 years 1.07
Extreme 1.07
11.97
10 years 1.07
Extreme 1.07
16.7
Manager TitleAgeSince
Chief Executive Officer 54 2011-12-31
Director of Finance/CFO 61 2024-08-30
Chief Tech/Sci/R&D Officer - 2023-10-31
Director TitleAgeSince
Director/Board Member 54 2005-08-31
Director/Board Member 60 2009-04-30
Director/Board Member 76 2010-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
6/3/26 Buy

Chief Executive Officer

250,000 0.4144%
3/27/26 Free

Chief Executive Officer

2,512,828 4.1767%
3/19/26 Buy

Chairman

70,000 0.1164%
Change 5-day change 1-year change 3-year change Capi.($)
-1.45%+1.49%-72.41%-78.88% 82.04M
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.27% 62.49B
+0.50%+7.13%+33.27%+16.01% 26.34B
-3.21%-7.27%-17.10%+356.10% 26.21B
-2.64%-0.69%-0.17%-13.01% 24.13B
+0.71%+8.03%+25.03%-12.74% 20.72B
+2.12%-5.86%+161.58%+329.34% 15.36B
-0.22%+3.99%+45.54%+172.46% 14.46B
+0.73%+1.71%-5.51%+849.47% 14.24B
Average -0.34%+1.72%+25.67%+179.60% 27.49B
Weighted average by Cap. -0.28%+1.49%+35.65%+148.15%

Financials

2026 *2027 *
Net sales - 6.72M 5.86M 5.53M 5.02M 9.41M 645M 9.45M 66.27M 25.57M 328M 25.24M 24.68M 1.05B
Net income -20.47M -17.85M -16.86M -15.31M -28.68M -1.96B -28.8M -202M -77.92M -999M -76.9M -75.2M -3.21B -17.4M -15.17M -14.32M -13.01M -24.37M -1.67B -24.47M -172M -66.21M -849M -65.35M -63.9M -2.73B
Net Debt - -
Logo Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Employees
6
Date Price Change Volume
26-09-18 US$1.360 -1.45% 367,724
26-09-17 US$1.380 +0.73% 394,917
26-09-16 US$1.370 0.00% 791,858
26-09-15 US$1.370 -6.16% 833,612
26-09-14 US$1.460 +8.96% 1,168,295
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.360USD
Average target price
6.600USD
Spread / Average Target
+385.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALDX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!